Abstract
Objectives
We used the status of microvascular invasion (MVI) at primary resection to help treatment selection for hepatitis B virus–positive (HBV+) recurrent hepatocellular carcinoma (rHCC) patients in Barcelona Clinic Liver Cancer (BCLC) stage B-C.
Methods
From 2009 to 2017, we enrolled 221 consecutive HBV+ rHCC patients at BCLC stage B-C who underwent re-resection (RR), radiofrequency ablation (RFA), or transarterial chemoembolization (TACE). Post recurrence survival (PRS) and overall survival (OS) were compared between RR/RFA and TACE according to MVI status. A one-to-one propensity score matching analysis was performed.
Results
For MVI(−) patients, the median PRS was 62.3 months for the RR/RFA group and 21.1 months for the TACE group (p = 0.039). The corresponding OS was 71.4 months and 26.6 months, respectively (p = 0.010). For MVI(+) patients, the median PRS in the RR/RFA group and TACE group was 14.7 months and 10.1 months (p = 0.115). The corresponding OS was 23.4 months and 16.4 months, respectively (p = 0.067). After matching, the dominance of RR/RFA over TACE remained in MVI(−) patients for both PRS (62.3 months vs 15.3 months, p = 0.019) and OS (98.1 months vs 33.4 months, p = 0.046). No significant difference was found in MVI(+) patients for either PRS (14.7 months vs 11.8 months, p = 0.593) or OS (23.4 months vs 28.1 months, p = 0.662).
Conclusions
MVI status definitely helps select treatment options in HBV+ rHCC patients. For MVI(−) patients, RR/RFA provided better survival than TACE while for MVI(+) patients, TACE shared similar survival outcomes.
Key Points
• This study aimed at the determination of the optimal treatment options (ablation /resection vs TACE) in case of recurrent HBV-related HCC.
• It showed that MVI status, established at primary resection of HCC, was a powerful marker for selecting the best treatment option in these patients.
• In MVI(−) patients, RR/RFA achieved a better survival than TACE. In MVI(+) patients, TACE shared similar survival.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
More than 70% of patients with hepatocellular carcinoma (HCC) resection will recur within 5 years, raising the question of the optimal treatment strategy after recurrence.
Re-resection, radiofrequency ablation (RFA), and transarterial chemoembolization (TACE) have been performed in recurrent hepatocellular carcinoma (rHCC) at Barcelona Clinic Liver Cancer (BCLC) stage B-C, but the reported results are quite controversial [1,2,3]. A possible reason is the insufficient recognition of the biological variability of HCC when considering treatment selection for recurrence. Pathological characteristics of the primary tumor, including the presence or absence of microvascular invasion (MVI(+) and MVI(−)) respectively, are predictors of postsurgical recurrence [4,5,6]. MVI status has been used as a predictor for decision-making of additional treatment after initial resection [7]. Jin et al [8] compared TACE and surgery/RFA in rHCC patients within BCLC stage 0-A and found that TACE had a better survival over surgery for early recurrent MVI(+) patients. Conversely, Hou et al [9] indicated that a repeat hepatectomy had a better survival for rHCC patients if the primary tumor was MVI(+) and within the Milan criteria, not mentioning the stage of rHCC. MVI status is probably helpful in selecting the appropriate treatment for rHCC at an early stage. However, the relevance of MVI status in rHCC patients at intermediate-advanced stage is still lacking, while they represent almost half of all rHCC population [10, 11].
The aim of this retrospective study was to compare the benefit of different treatments in recurrent HBV-related HCC patients at BCLC stage B-C, according to the presence or absence of MVI. A propensity score matching (PSM) was also performed for a balanced baseline.
Methods
Study design
Comprehensive data of 2137 consecutive HCC patients who initially underwent liver resection at either the First Affiliated Hospital of Sun Yat-sen University or the Cancer Center of Sun Yat-sen University from June 2009 to June 2017 were collected. This study was conducted in accordance with the Declaration of Helsinki (1964) and approved by the ethical committees of these two centers. The inclusion criteria for the rHCC patients were (a) received curative resection for primary tumor without adjuvant therapy; (b) first recurrence after resection; (c) recurred tumor at BCLC stage of B/C [12]; (d) Child-Pugh grade A-B; (e) Eastern Cooperative Oncology Group (ECOG) performance status 0–1. The exclusion criteria included (a) missing data about MVI at primary resection; (b) receive other treatments for rHCC; (c) HBsAg-negative. At last, 221 rHCC patients were enrolled in this study.
HCC and recurrence were diagnosed mainly by the non-invasive criteria following the European Association for the Study of the Liver, European Organization for Research and Treatment of Cancer (EASL-EORTC) guideline [13, 14]. Patients were classified as BCLC stage B according to following criteria: multinodular tumors more than 3 or multinodular tumors larger than 3 cm and ECOG performance status 0. Patients were classified as BCLC stage C if with macrovascular invasion or extrahepatic metastasis or ECOG performance status 1. MVI status in the resected specimen of primary HCC was confirmed by two experienced pathologists in hepatology over 5 years. Evaluation of postsurgical recurrence was performed every 3 months for the first two years, 3–6 months thereafter. The contrast-enhanced ultrasound (US) and dynamic contrast-enhanced liver computed tomography (CT) were used for recurrence evaluation. Diagnosis criteria and the follow-up schedule of rHCC were referred to that of the primary HCC. The post recurrence survival (PRS) was defined as the time interval from the date of rHCC treatments to the date of death from any cause or to the date of the last follow-up visit. Overall survival (OS) in this study was defined as the interval between the first resection of HCC to the date of death from any cause or to the date of the last follow-up visit.
Treatment selection
The decision of treatment option was initiated by a multidisciplinary team including surgeons, interventional radiologists, and oncologists. The treatment-related issues such as possible efficacy, costs, and the risks of complication during and after different treatments were informed to the patient, who would make the final decision then.
Treatment protocol
Re-resection procedure
Re-resection was performed under general anesthesia by surgeons with 10–40 years of experience. Generally, the type of surgery was decided according to a routine preoperative discussion for each patient. Anatomic resection, defined as the complete removal of at least one Couinaud segment containing the tumor and the corresponding hepatic territory, was routinely performed if possible. Other types of surgery, such as wedge resection or tumor enucleation, were classified as non-anatomic resection. The surgical approach was chosen based on the liver remnant, tumor location, and preference of the operator. Intraoperative US was used to assist in operative evaluation.
RFA procedure
RFA was carried out by three doctors with over 10 years of ablation experience. RFA was performed under local anesthesia with LeVeen electrodes (Boston Scientific), Starburst XL electrodes (RITA Medical Systems), or Cool-tip electrodes (Valleylab). The electrode was percutaneously inserted under the real-time US guidance through the guiding needle. RFA was performed with the intent to completely eradicate the tumor with an ablative margin of at least 5 mm. Multiple overlapping ablations were performed for lesions larger than 3 cm. After RFA, the needle track was coagulated for reducing bleeding and tumor seeding.
TACE procedure
TACE was carried out by two radiologists with over 5 years of experience. A selective catheter was inserted into the tumor-feeding arteries after evaluating arterial blood supply of the liver and confirming patency of the portal vein by visceral angiography. Hepatic artery infusion chemotherapy was performed using carboplatin 300 mg (Bristol-Myers Squibb). Subsequently, chemolipiodolization was performed using epirubicin 50 mg (Pharmorubicin, Pfizer), and mitomycin C 8 mg (Zhejiang Hisun Pharmaceutical Co. Ltd.) mixed with 5 mL of lipiodol (Lipiodol Ultra- Fluide; Guerbet). Embolization was finally performed with absorbable gelatin sponge particles (Gelfoam; Hanzhou Alc Ltd., 1–2 mm in diameter) or polyvinyl alcohol particles (Alicon Pharm SCT&TEC CO., Ltd., 350–560 μm in diameter) until the blood flow was static for more than 10 successive heartbeats. After embolization, angiography was performed to determine the extent of vascular occlusion and to assess blood flow in other arterial vessels. Tumor response was evaluated 4 weeks after each treatment with TACE. Repeated TACE was performed if clinical necessary according to the follow-up images and the time interval was 6–8 weeks between 2 TACE procedures.
Statistical analysis
Normal distribution test was performed for continuous variables. Continuous variables which obey the normal distribution were presented as means ± standard deviation and others as median and quartile. Categorical variables were presented as numbers and percentages. Differences between the RR/RFA group and the TACE group were compared with the t test or the Mann–Whitney test for continuous variables and χ2 test for categorical variables. Survival curves were generated by the Kaplan–Meier method and compared by the log-rank test. The potential survival predictors were analyzed by univariate and multivariate Cox proportional hazard regression models. A strong correlation between time to recurrence (TTR) and MVI at primary resection was observed; therefore, TTR was not included in the multivariate Cox regression models. Log-log plot of survival and the Schoenfeld residuals test were used to check the proportional hazards assumption.
Furthermore, PSM was performed to diminish the bias. Patients received RR/RFA and TACE in different MVI patterns were separately matched based on logistic regression model. Propensity scores were estimated according to significant variates in the cox model and the significantly different characteristics between the two treatment groups [15]. One-to-one matching without replacement was performed using a caliper width of 0.2 standard deviation of the logit of the propensity score [16].
Statistical significance was considered as a two-sided p value of less than 0.05. The above statistical analysis was performed with the STATA/MP 14.0.
Results
Baseline characteristics
The flow chart of patient selection was shown in Fig. 1. The baseline characteristics of rHCC patients at BCLC stage B-C are displayed in Table 1. Detailed baseline characteristics for primary tumor are shown in Supplementary Table 1–2. Patients were separated into two groups according to the MVI status at primary resection. Sixty-six rHCC patients were MVI-negative and 155 patients were MVI(+). MVI(+) rHCC patients at primary resection had a higher level of GGT, AST, and AFP. Most of the MVI(+) patients (92.3%) recurred within 1 year, while the ratio was 71.2% for MVI(−) patients (p < 0.001). More patients received TACE than RR/RFA in both groups. The median time of TACE performed was once, with details listed in Supplementary Table 3. Distributions of treatment strategies were similar in the two groups.
Survival outcomes
Median PRS of all rHCC patients at BCLC stage B-C was 14.7 months. MVI(−) patients with had a significant longer PRS than MVI(+) patients (23.4 vs 11.1 months, p < 0.001) (Fig. 2a). Median OS was 22.7 months for all rHCC patients. Similar to the PRS, OS of patients with MVI(−) was longer than that of patients with MVI(+) (33.4 vs 16.8 months, p < 0.001) (Fig. 2b).
Univariate and multivariate analysis
The results of univariate and multivariate analysis of PRS are shown in Table 2. GGT > 50 U/L (hazard ratio (HR) = 1.79, p = 0.001), AST > 40 U/L (HR = 1.93, p < 0.001), MVI(+) at primary resection (HR = 1.49, p = 0.033), macrovascular invasion at recurrence (HR = 1.58, p = 0.026), and receiving RR/RFA (HR = 0.65, p = 0.045) were independent prognostic factors of PRS. Analyses of OS were performed as well. AFP of primary tumor > 200 ng/mL (HR = 1.44, p = 0.031), size of primary tumor >5 cm (HR = 1.63, p = 0.012), MVI(+) at primary resection (HR = 1.72, p = 0.004), macrovascular invasion at recurrence (HR = 1.77, p = 0.005), and receiving RR/RFA for rHCC (HR = 0.54, p = 0.004) were independent prognostic factors of OS.
Subgroup analysis
MVI(−) group
Baseline characteristics of rHCC MVI(−) patients are shown in Table 3. Most patients (91.7%) in the TACE group were multifocal, compared with 66.7% in the curative treatment group (p = 0.026). As for the TTR, 81.3% of the patients in the TACE group were less than 1 year. The corresponding ratio was 44.4% in the RR/RFA group. PRS was significantly longer in the RR/RFA group (62.3 vs 21.1 months, p = 0.039) (Fig. 3a). Considering the uneven baseline, a PSM was performed for survival comparison. After PSM, all characteristics were balanced in the two treatment groups. The median PRS was 15.3 months for the TACE group and 62.3 months for the RR/RFA group (p = 0.019) (Fig. 3b). Median OS was significantly longer in the RR/RFA group (71.4 vs 26.6 months, p = 0.010). Median OS after PSM was 98.1 months for the RR/RFA group and 33.4 months for the TACE group (p = 0.046).
MVI(+) group
The same comparisons were done for MVI(+) patients. Baseline characteristics of MVI(+) rHCC patients were shown in Table 4. The ratio of multifocal tumors was larger in the TACE group compared to that in the RR/RFA group (87.8% vs 53.1%, p < 0.001). The unbalanced distribution of TTR in the MVI(−) patients disappeared in the MVI(+) subgroup. PRS was not significantly differed between the RR/RFA group and the TACE group (14.7 vs 10.1 months, p = 0.115) (Fig. 4a). After PSM, the median PRS was 11.8 months for the TACE group and 14.7 months for the RR/RFA group (p = 0.593) (Fig. 4b). Similar trends were observed in the analysis of OS. Median OS was 23.4 months for the RR/RFA group and 16.4 months for the TACE group (p = 0.067). The corresponding figures were 23.4 months and 28.1 months after PSM, respectively (p = 0.662).
Discussion
Our study found that for selected HBV-related rHCC patients at BCLC stage B-C, RR/RFA could provide better efficacy than TACE in MVI(−) patients, while TACE shared a similar efficacy with RR/RFA if the patients were MVI(+).
Previous studies have emphasized the prognostic importance of pathological profile at primary resection for rHCC patients, especially the existence of MVI. Yet the role of MVI status in the treatment selection was rarely discussed. This article first showed the possibility to use MVI status as a predictor for treatment selection in selected rHCC patients within BCLC stage B-C. According to our results, RR/RFA provided a better survival than TACE for rHCC patients at BCLC stage B-C if the patients were MVI(−). The comparison of surgery, RFA, and TACE in primary HCC has been widely discussed, especially in BCLC stage B-C. Surgery and RFA had a survival advantage in the majority of these studies [17,18,19,20,21,22]. The limited remnant liver volume might cause difficulty in performing aggressive treatments. Yet early studies showed that re-resection could be safely performed even for patients who received major resection as the first treatment, and by applying approaches like laparoscopic resection, similar perioperative outcomes to primary resection could be achieved [23, 24]. Therefore, we recommend RR/RFA as the first-line treatment for MVI(−) patients at BCLC stage B-C. Survival was not significantly different in patients with MVI(+) whatever the treatment option. There might be two explanations for this difference. Firstly, MVI(+) patients’ recurrent tumor might be more aggressive. According to our results, the level of AFP was significantly higher in the MVI(+) group. The correlation of high serum AFP level and MVI in primary HCC has been proved in early studies [25, 26]. Elevated AFP translates a more aggressive tumor behavior and a higher degree of tumor cell proliferation [27,28,29]. The aggressive tumor behavior might hamper the theoretical benefit of curative over palliative treatments. Secondly, as previous studies, our MVI(+) patients were more likely to recur within 1 year. This may indicate that rHCC in these patients is a dissemination of the original tumor via the vascular circulation before primary resection rather than de novo [4]. The behavior of these disseminated tumors is likely similar to that of the primary tumor, prompting recurrence even after curative-intend treatments. However, repeatable TACE could provide a sustained devascularization for rHCC and might prevent potential hematogenous metastasis. This might be one explanation for the similar efficacy of TACE vs RR/RFA in these patients. Therefore, TACE should be considered as the first choice for rHCC MVI(+) patients at BCLC stage B-C.
Another interesting finding was that results showed that 92.3% of MVI+ patients recurred within the year following surgery. This leads to a further emphasis on the necessity of assessing MVI status for naïve HCC patients. Lately published articles showed promising predictive performance of MVI scoring systems [30, 31]. Predicting model based on radiomics also showed satisfactory accuracy [32,33,34]. However, clinical use of these predicting systems is limited due to the lack of multiregional validation. Further studies are still needed.
There are some study limitations. First, we did not make a comparison of treatments mentioned in this study with sorafenib, which is the standard treatment for advanced HCC patients. This is because the proportion of patients receiving sorafenib is quite low due to the limited cost-effectiveness, making the retrospective data of sorafenib treatment very finite. Second, despite the fact that TTR was reported to be a prognostic factor of rHCC, we did no subgroup analysis by TTR. Over 90% of patients in the MVI(+) group and about 70% of patients in the MVI(−) group recurred within 1 year, making the subgroup comparison hard to perform.
In conclusion, we found that MVI at primary resection could be used as a marker to guide the treatment selection of HBV+ rHCC at BCLC stage B-C. For patients with MVI(−) at primary resection, curative treatments are recommended, while for MVI(+) patients, TACE, RR, and RFA shared similar survival benefits.
Abbreviations
- BCLC:
-
Barcelona Clinic Liver Cancer
- ECOG:
-
Eastern Cooperative Oncology Group
- HBV:
-
Hepatitis B virus
- HR:
-
Hazard ratio
- MVI:
-
Microvascular invasion
- OS:
-
Overall survival
- PRS:
-
Post recurrence survival
- RFA:
-
Radiofrequency ablation
- rHCC:
-
Recurrent hepatocellular carcinoma
- RR:
-
Re-resection
- TACE:
-
Transarterial embolization
References
Koh PS, Chan ACY, Cheung TT et al (2016) Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis. HPB (Oxford) 18:72–78. https://doi.org/10.1016/j.hpb.2015.07.005
Dai WC, Cheung TT (2016) Strategic overview on the best treatment option for intrahepaitc hepatocellular carcinoma recurrence. Expert Rev Anticancer Ther 16:1063–1072. https://doi.org/10.1080/14737140.2016.1226136
Joliat G-R, Allemann P, Labgaa I et al (2017) Treatment and outcomes of recurrent hepatocellular carcinomas. Langenbecks Arch Surg 402:1–8. https://doi.org/10.1007/s00423-017-1582-9
Imamura H, Matsuyama Y, Tanaka E et al (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38:200–207
Tung-Ping Poon R, Fan ST, Wong J (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232:10–24. https://doi.org/10.1097/00000658-200007000-00003
Ali MA, Li W-F, Wang J-H et al (2016) Impact of pathological features of primary hepatocellular carcinoma on the outcomes of intrahepatic recurrence management: single center experience from Southern Taiwan. HPB (Oxford) 18:851–860. https://doi.org/10.1016/j.hpb.2016.07.004
Pinyol R, Montal R, Bassaganyas L et al (2019) Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut 68:1065–1075. https://doi.org/10.1136/gutjnl-2018-316408
Jin Y-J, Lee J-W, Lee OH et al (2014) Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion. J Gastroenterol Hepatol 29:1056–1064. https://doi.org/10.1111/jgh.12507
Hou Y-F, Li B, Wei Y-G et al (2015) Second hepatectomy improves survival in patients with microvascular invasive hepatocellular carcinoma meeting the Milan criteria. Medicine (Baltimore) 94:e2070–e2078. https://doi.org/10.1097/MD.0000000000002070
Tabrizian P, Jibara G, Shrager B et al (2015) Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 261:947–955. https://doi.org/10.1097/SLA.0000000000000710
He W, Peng B, Tang Y et al (2018) Nomogram to predict survival of patients with recurrence of hepatocellular carcinoma after surgery. Clin Gastroenterol Hepatol 16:756–764.e10. https://doi.org/10.1016/j.cgh.2017.12.002
Bruix J, Reig M, Sherman M (2016) Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150:835–853. https://doi.org/10.1053/j.gastro.2015.12.041
European Association for Study of Liver, European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 48:599–641. https://doi.org/10.1016/j.ejca.2011.12.021
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association For The Study Of The Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236. https://doi.org/10.1016/j.jhep.2018.03.019
Brookhart MA, Schneeweiss S, Rothman KJ et al (2006) Variable selection for propensity score models. Am J Epidemiol 163:1149–1156. https://doi.org/10.1093/aje/kwj149
Austin PC (2008) The performance of different propensity-score methods for estimating relative risks. J Clin Epidemiol 61:537–545. https://doi.org/10.1016/j.jclinepi.2007.07.011
Roayaie S, Jibara G, Tabrizian P et al (2015) The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology 62:440–451. https://doi.org/10.1002/hep.27745
Kokudo T, Hasegawa K, Matsuyama Y et al (2016) Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol 65:938–943. https://doi.org/10.1016/j.jhep.2016.05.044
Zhong J-H, Ke Y, Gong W-F et al (2014) Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg 260:329–340. https://doi.org/10.1097/SLA.0000000000000236
Kim H, Ahn SW, Hong SK et al (2017) Survival benefit of liver resection for Barcelona clinic liver cancer stage B hepatocellular carcinoma. Br J Surg 104:1045–1052. https://doi.org/10.1002/bjs.10541
Torzilli G, Belghiti J, Kokudo N et al (2013) A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg 257:929–937. https://doi.org/10.1097/SLA.0b013e31828329b8
Yuan B-H, Yuan W-P, Li R-H et al (2016) Propensity score-based comparison of hepatic resection and transarterial chemoembolization for patients with advanced hepatocellular carcinoma. Tumour Biol 37:2435–2441. https://doi.org/10.1007/s13277-015-4091-x
Minagawa M, Makuuchi M, Takayama T, Kokudo N (2003) Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 238:703–710. https://doi.org/10.1097/01.sla.0000094549.11754.e6
Goh BKP, Syn N, Teo JY et al (2018) Perioperative outcomes of laparoscopic repeat liver resection for recurrent HCC: comparison with open repeat liver resection for recurrent HCC and laparoscopic resection for primary HCC. World J Surg:1–8. https://doi.org/10.1007/s00268-018-4828-y
Lei Z, Li J, Wu D et al (2016) Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the Milan criteria. JAMA Surg 151:356–363. https://doi.org/10.1001/jamasurg.2015.4257
Rodríguez-Perálvarez M, Luong TV, Andreana L et al (2013) A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg Oncol 20:325–339. https://doi.org/10.1245/s10434-012-2513-1
Dudich E, Semenkova L, Gorbatova E et al (1998) Growth-regulative activity of human alpha-fetoprotein for different types of tumor and normal cells. Tumor Biol 19:30–40
Wang XW, Xu B (1998) Stimulation of tumor-cell growth by alpha-fetoprotein. Int J Cancer 75:596–599
Tajiri H, Takano T, Tanaka H et al (2016) Hepatocellular carcinoma in children and young patients with chronic HBV infection and the usefulness of alpha-fetoprotein assessment. Cancer Med 5:3102–3110. https://doi.org/10.1002/cam4.917
Zhang X-P, Wang K, Wei X-B, et al (2019) An eastern hepatobiliary surgery hospital microvascular invasion scoring system in predicting prognosis of patients with hepatocellular carcinoma and microvascular invasion after R0 liver resection: a large-scale, multicenter study. Oncologist 2018–0868. https://doi.org/10.1634/theoncologist.2018-0868
Lee S, Kang TW, Song KD et al (2019) Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. Ann Surg:1–8. https://doi.org/10.1097/SLA.0000000000003268
Feng ST, Jia Y, Liao B et al (2019) Preoperative prediction of microvascular invasion in hepatocellular cancer: a radiomics model using Gd-EOB-DTPA-enhanced MRI. Eur Radiol 89:500–512. https://doi.org/10.1007/s00330-018-5935-8
Ma X, Wei J, Gu D et al (2019) Preoperative radiomics nomogram for microvascular invasion prediction in hepatocellular carcinoma using contrast-enhanced CT. Eur Radiol 136:1–11. https://doi.org/10.1007/s00330-018-5985-y
Xu X, Zhang H-L, Liu Q-P et al (2019) Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma. J Hepatol 70:1133–1144. https://doi.org/10.1016/j.jhep.2019.02.023
Acknowledgments
We thank the kind statistical help provided by the clinical trials unit.
Funding
This work is supported by grants from the National Natural Science Foundation of China (NSFC, Nos. 81770608 and 81801703), the National Science Fund for Distinguished Young Scholars (No. 81825013), the Natural Science Foundation of Guangdong Province (No. 2018A030310282), and the National high level talents special support plan—“Ten thousand plan”—Young top-notch talent support program and the Kelin Outstanding Young Scientist of the First Affiliated Hospital of Sun Yet-sen University (2017), Guangdong Medical Science and Technology Foundation (A2017191), Science and Technology Program of Guangzhou, China (No. 201704020215).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Guarantor
The scientific guarantor of this publication is Sui Peng.
Conflict of interest
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
One of the authors (Bin Li) has significant statistical expertise.
Informed consent
Written informed consent was waived by the Institutional Review Board.
Ethical approval
Institutional Review Board approval was obtained.
Study subjects or cohorts overlap
Some study subjects or cohorts have been previously reported in the American Journal of Translational Research. The former article focused on characteristics of patients with MVI(+). To explore the role of MVI in guidance of treatments for HBV+ recurrent intermediate-advanced HCC, we limited the population to HBV+ patients and further added data of patients with MVI(−) at primary resection. Therefore, the role of MVI in treatment selection for HBV+ rHCC patients could only be evaluated in this study.
Methodology
• retrospective
• observational
• multicenter study
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOCX 1846 kb)
Rights and permissions
About this article
Cite this article
Chen, SL., Xiao, H., Xie, ZL. et al. The presence of microvascular invasion guides treatment strategy in recurrent HBV-related HCC. Eur Radiol 30, 3473–3485 (2020). https://doi.org/10.1007/s00330-019-06640-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-019-06640-8